Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cardio Diagnostics Holdings In - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CDIO
Nasdaq
8731
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cardio Diagnostics Holdings In
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session
- Mar 14th, 2024 12:31 pm
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
- Mar 5th, 2024 1:31 pm
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
- Feb 15th, 2024 1:46 pm
Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters
- Feb 7th, 2024 1:31 pm
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests
- Feb 5th, 2024 1:31 pm
Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor
- Jan 24th, 2024 1:31 pm
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
- Jan 8th, 2024 1:31 pm
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
- Jan 4th, 2024 4:36 pm
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
- Jan 3rd, 2024 1:31 pm
American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.’s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code
- Jan 2nd, 2024 1:31 pm
11 Hot Healthcare Stocks To Buy Now
- Dec 28th, 2023 12:35 am
Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors
- Dec 21st, 2023 2:21 pm
Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement
- Dec 6th, 2023 1:31 pm
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 4th, 2023 10:38 pm
American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc’s Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes
- Nov 28th, 2023 1:31 pm
Cardio Diagnostics Establishes A New Partnership To Facilitate Global Footprint And Expansion Beyond North America With India-Based Aimil Ltd.
- Nov 20th, 2023 2:00 pm
Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association
- Nov 20th, 2023 1:31 pm
Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients
- Nov 7th, 2023 2:01 pm
Cardio Diagnostics Holdings, Inc Receives Innovative Technology Contract from Vizient for Its Novel AI-Driven Precision Heart Disease Tests – Epi+Gen CHD & PrecisionCHD
- Oct 31st, 2023 1:01 pm
Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce Cardiovascular Epigenetic Technologies to India
- Oct 17th, 2023 1:01 pm
Scroll